Four therapeutic genes have been inserted and one ‘unwanted’ gene removed from the DNA of preclinical models in a single intervention
The Cell Engineering team at Integra Therapeutics has conducted a preclinical trial demonstrating the FiCAT platform’s ability to simultaneously insert up to four genes in a therapeutic payload into a defined, safe location in the genome, while deactivating an unwanted gene—all in a single step. These results are significant because current CAR-T cell therapy manufacturing […]
Integra Therapeutics unveils core values to strengthen a culture of innovation and well-being
Integra Therapeutics has introduced its core values, a set of principles that will guide the company’s internal culture as well as its business and scientific activities as it continues to develop pioneering advances in the field of gene-writing. The core values were defined through a collaborative process involving the entire team, including a series of […]
Integra Therapeutics appoints Miles Gerson as Independent Chairman
Integra Therapeutics announced today the appointment of Miles Gerson as the Independent Chairman of its Board of Directors. His incorporation strengthens the company’s governance and supports its strategic vision as it moves toward key development milestones. Mr. Gerson brings more than 20 years of experience in healthcare venture investing, business development, licensing, technology transfer and […]
Generative AI is more efficient than nature at designing proteins to edit the genome
Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life Sciences (MELIS) and the Center for Genomic Regulation (CRG), have designed and experimentally validated new synthetic proteins that can edit the human genome more efficiently than proteins provided by nature. This work, a global pioneer published today in […]
Integra Therapeutics secures €10.7 million investment round to advance development of FiCAT gene writing platform and preclinical validation of CAR-T therapies
Integra Therapeutics, a global leader in cutting-edge gene writing tools to improve the efficacy, precision and safety of advanced therapies, announced it has closed a €10.7 million pre Series A round of investment. The funds come from new investors like the EIC Fund —the venture capital arm of the European Innovation Council (EIC) with the […]
Integra Therapeutics announces new pre-clinical data at 28th Annual Meeting of American Society of Gene and Cell Therapy
Integra Therapeutics, a global leader in creating cutting-edge gene-writing tools to improve the efficacy, precision and safety of advanced therapies, today announced it will be presenting new pre-clinical data at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from May 13 to 17 in New Orleans. “The […]
Integra Therapeutics, first company to move into Advanced Therapies Platform at SJD Barcelona Children’s Hospital
Integra Therapeutics has moved its headquarters to the new Advanced Therapies Platform at SJD Barcelona Children’s Hospital. It is the first company to be located in this advanced therapies center that occupies 1,280 square meters in the Pediatric Cancer Center at SJD Hospital and has a research and development area for new therapies, and a […]
Integra Therapeutics part of Spanish Government presentation of ‘HispanIA 2040’ as an AI for health success story
This week, Integra Therapeutics took part in an event to present the report HispanIA 2040: cómo la inteligencia artificial mejorará nuestro futuro (Spanish AI 2040: artificial intelligence for a better future) at the Ramón Areces Foundation in Madrid, with President of the Government of Spain Pedro Sánchez. Also present at this event were Minister for […]
Caszyme and Integra Therapeutics sign licensing agreement for novel CRISPR Cas12l nucleases
Caszyme, a pioneer in the development and application of CRISPR gene editing technology, and Integra Therapeutics, a company leading the way in creating advanced therapies based on next-generation gene-writing tools, today announced a licensing agreement for the use of Caszyme’s novel Cas12l nucleases to develop safer and more efficient gene and cell therapies. The agreement […]
Integra Therapeutics to receive up to €10.5 million from European Commission for its FiCAT advanced therapies platform
Integra Therapeutics, a global leader in creating cutting-edge gene writing tools to make advanced therapies safer and more effective, will receive a grant of €2.5 million and equity investment of up to €8 million from the European Commission via the European Innovation Council (EIC) Accelerator program. Of a total of 969 deeptech companies, the EC […]